Luis Robles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luis Robles has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
A. Franco
12 de Octubre University Hospital
1 shared publicationAlbert Abad
Department of Medical Oncology, Instituto Oncológico Dr. Rosell, Barcelona, Spain
1 shared publication- Alfredo Carrato
Department of Oncology, Ramón y Cajal University Hospital
1 shared publication - Alicia Cazorla
Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain
1 shared publication - Ana Isabel Ferrer Pérez
Aoup Paolo Giaccone, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo/IT
1 shared publication - Andres Jesus Muñoz Martin
Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1773
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary. To evaluate low molecular weight heparin (LMWH) for primary thromboprophylaxis in metastatic CRC outpatients receiving first-line systemic cancer therapy. PROTINCOL (NCT05625932) is a randomized, open-label (PROBE), multicenter study. Patients will receive tinzaparin (75 IU/kg) or no pharmacological prophylaxis for 4 months and will be stratified based on: BRAF/RAS mutation, primary resection tumor and antiangiogenic therapy. The study outcomes will be assessed by a blinded central independent adjudication committee. The primary efficacy endpoints will include the cumulative incidence of any venous thromboembolism (VTE) event (symptomatic or incidental) including symptomatic central venous catheter VTE. Secondary variables will be clinically relevant bleedings, health-related quality of life and the predictive value of validated risk assessment scales of VTE, including the genetic risk score (TIC-ONCO). Our hypothesis is that prophylactic LMWH will reduce the 55% relative risk to an estimated VTE incidence of 13.5%. A total of 526 patients will be required. Risk prediction of chemotherapy-associated VTE is a compelling challenge in oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Patients with a single type of metastatic cancer with a high risk of VTE will be selected for study inclusion. For the first time in ambulatory prophylaxis of cancer-associated thrombosis, a precision medicine approach will be used in a clinical trial. If the individualization of antithrombotic prophylaxis can reduce the complications of outpatient cancer treatment and be cost effective, it would be of great value in the future care of patients with metastatic CRC. NCT05625932. Registered on 15 Nov 2022. The trial started recruitment on March 2023.
- 17 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1773
Open AccessTinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary. To evaluate low molecular weight heparin (LMWH) for primary thromboprophylaxis in metastatic CRC outpatients receiving first-line systemic cancer therapy. PROTINCOL (NCT05625932) is a randomized, open-label (PROBE), multicenter study. Patients will receive tinzaparin (75 IU/kg) or no pharmacological prophylaxis for 4 months and will be stratified based on: BRAF/RAS mutation, primary resection tumor and antiangiogenic therapy. The study outcomes will be assessed by a blinded central independent adjudication committee. The primary efficacy endpoints will include the cumulative incidence of any venous thromboembolism (VTE) event (symptomatic or incidental) including symptomatic central venous catheter VTE. Secondary variables will be clinically relevant bleedings, health-related quality of life and the predictive value of validated risk assessment scales of VTE, including the genetic risk score (TIC-ONCO). Our hypothesis is that prophylactic LMWH will reduce the 55% relative risk to an estimated VTE incidence of 13.5%. A total of 526 patients will be required. Risk prediction of chemotherapy-associated VTE is a compelling challenge in oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Patients with a single type of metastatic cancer with a high risk of VTE will be selected for study inclusion. For the first time in ambulatory prophylaxis of cancer-associated thrombosis, a precision medicine approach will be used in a clinical trial. If the individualization of antithrombotic prophylaxis can reduce the complications of outpatient cancer treatment and be cost effective, it would be of great value in the future care of patients with metastatic CRC. NCT05625932. Registered on 15 Nov 2022. The trial started recruitment on March 2023.
- 1 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , 1123-1132
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- 1 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , 1123-1132
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- Open Access
- 2 December 2014
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 31 (4) , 769-74
Asociaciones público-privadas para servicio de salud: ¿la solución al sistema de salud peruano?
Asociaciones público-privadas para servicio de salud: ¿la solución al sistema de salud peruano?
- 2 December 2014
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 31 (4) , 769-74
Open AccessAsociaciones público-privadas para servicio de salud: ¿la solución al sistema de salud peruano?
Asociaciones público-privadas para servicio de salud: ¿la solución al sistema de salud peruano?
- 1 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S146-S147
614 Characterization of Oncogenesis Process of Sporadic and Familial Epithelial Ovarian Cancer (EOC)
- 1 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S146-S147
614 Characterization of Oncogenesis Process of Sporadic and Familial Epithelial Ovarian Cancer (EOC)
- Open Access
- 1 August 2009
- Published by SciELO Espana/Repisalud in Revista Española de Enfermedades Digestivas
- Vol. 101 (8) , 536-540
Surgical management of hereditary colorectal cancer: surgery based on molecular analysis and family history
The importance of colorectal cancer (CRC) is increasing. A proportion show a hereditary component, as in Lynch syndrome and Familial Adenomatous Polyposis, and a recently defined entity as well, namely, Familial Colorectal Cancer type X. The high probability to develop CRC in these groups may, at the time of recognition, change surgical management, including its timing or even the surgical technique. In some cases prophylactic surgery can play an important role. The possibility of using tools that allow recognition of the aforementioned syndromes, including microsatellite instability, immunohistochemistry for DNA mismatch repair system proteins, and especially their mutations, is on the basis of therapeutic strategies that differ from those employed in sporadic CRC cases.
- 1 August 2009
- Published by SciELO Espana/Repisalud in Revista Española de Enfermedades Digestivas
- Vol. 101 (8) , 536-540
Open AccessSurgical management of hereditary colorectal cancer: surgery based on molecular analysis and family history
The importance of colorectal cancer (CRC) is increasing. A proportion show a hereditary component, as in Lynch syndrome and Familial Adenomatous Polyposis, and a recently defined entity as well, namely, Familial Colorectal Cancer type X. The high probability to develop CRC in these groups may, at the time of recognition, change surgical management, including its timing or even the surgical technique. In some cases prophylactic surgery can play an important role. The possibility of using tools that allow recognition of the aforementioned syndromes, including microsatellite instability, immunohistochemistry for DNA mismatch repair system proteins, and especially their mutations, is on the basis of therapeutic strategies that differ from those employed in sporadic CRC cases.